Studies of cognitive behavioral therapy in people
22 studies gave cognitive behavioral therapy to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on brain-predicted age differenceβ = 0.01 years, 95% CI [-0.82, 0.84]; p = .985 | Randomized trial | 38 peoplerelatively youngPatient cohorts | Journal of psychiatric research, Oct 16, 2026 |
up: Improves hot flush problem rating-1.47 points (95% CI -2.29 to -0.65, p < 0.001) down: Decreases menopausal symptoms | Randomized trial12 weeks | 100 peopleWomenPostmenopausal women | Maturitas, Aug 21, 2026 |
up: Improves physical activity adherence511.00 to 897.17 MET-minutes/week vs 360.67 to 310.83 MET-minutes/week down: Decreases systolic blood pressure-13.87 mmHg vs -5.60 mmHg no change: Has no effect on diastolic blood pressure | Trialtwo weeks | 30 peopleOlder adults; in older adults with hypertension | Jurnal Ners, Aug 21, 2026 |
down: Decreases vasomotor symptoms up: Improves quality of life down: Decreases anxiety | Randomized trial | 50 peopleWomenPostmenopausal women; postmenopausal women | Climacteric : the journal of the International Menopause Society, Jun 9, 2026 |
| Randomized trialone month | 135 peopleWomen60.1 ± 5.9 yearsPostmenopausal women; Older adults; with placebo or control | Current aging science, Apr 9, 2026 | |
| Randomized trial12 months | 155 peoplemean age 81.8 ± 6.4 years (range 64–96 years)Patients admitted for an acute physical illness aged 65 years or older with Hospital Anxiety and Depression Scale score > 7 | BMC geriatrics, Feb 7, 2026 | |
down: Decreases depression-42.1% (from M = 8.74 to M = 5.06, P = 0.001) down: Decreases anxiety-56.2% (from M = 6.98 to M = 3.06, P = 0.004) | Treated cohorteight sessions | 16 peopleWomenPostmenopausal women | Menopause (New York, N.Y.), Jan 27, 2026 |
down: Decreases insomniaps < .001 down: Decreases anxietyps < .001 up: Improves sleep efficiencyps < .001 | Randomized trial | 80 peopleolder adultsOlder adults; insomnia | medRxiv, Dec 12, 2025 |
down: Decreases anxiety down: Decreases somatic menopausal symptoms down: Decreases Insomnia Severity Index | Randomized trial6 weeks | 53 peopleWomenperimenopausal | Journal of mid-life health, Dec 8, 2025 |
down: Decreases menopausal symptoms up: Improves psychological well-being up: Improves quality of life | Trialshort-term | 24 peopleWomenPostmenopausal women; symptomatic perimenopausal and postmenopausal women | Post reproductive health, Nov 25, 2025 |
| Randomized trial8 weeks | 54 peopleBothmean age, 83.9 yearsPatients 65 years or older who had undergone TAVR and planned for home discharge | Journal of the American Geriatrics Society, Apr 2, 2025 | |
down: Decreases fatigue52.5 vs. 59.32 up: Improves self-efficacy7.23 vs. 5.89 up: Improves quality of life7.58 vs. 6.11 | TrialWeek 10 | 40 people85%, n = 34 were femalemean age of 70.28 years (SD = 6.76 years)Older adults aged ≥55 years with osteoarthritis or rheumatoid arthritis | Journal of gerontological nursing, May 1, 2024 |
up: Improves general healthd = 0.63 up: Improves physical Summary Indexd = 0.56 | Randomized trial8 weeks | 55 people63.6% were womenmean age of 53.0 years (SD = 5.8)Adults aged 45 years or older residing in Galicia with normal cognitive functioning | Digital health, Feb 20, 2024 |
no change: Has no effect on functional impairment | Randomized trial6 weeks | 1,120 peopleaged 55 years and olderOlder adults; living alone | Annals of internal medicine, Apr 24, 2023 |
down: Decreases worry | Randomized trialsix months after intervention completion | 500 peopleage 60+ yearsOlder adults; worried older adults | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, Feb 6, 2022 |
down: Decreases fatigue-7.2, 97.5% CI -12.7 to -1.7; P = 0.003 up: Improves quality of life10.2, 95% CI 2.4 to 17.9; P = 0.011 | Randomized trial12 weeks | 134 peopleBothmean 63 yearsOlder adults; advanced cancer patients with severe fatigue during treatment | Annals of oncology : official journal of the European Society for Medical Oncology, Jan 1, 2020 |
down: Decreases social anxiety symptom severityCohen's d = 1.46 up: Increases glutathione peroxidase no change: Has no effect on telomere length | Trial | 46 peopleBothPatient cohorts | Translational psychiatry, Dec 19, 2019 |
down: Decreases fear of falling down: Decreases fear avoidance behavior up: Improves balance | Randomized trial8 weeks | 89 peoplePatient cohorts | Stroke, Dec 7, 2018 |
| Randomized trial8 weeks | 119 peopleelderlyOlder adults | Revista espanola de geriatria y gerontologia, Nov 24, 2018 | |
down: Decreases depressionHADS 18.8 to 11.4 vs 18.1 to 21.6 in controls up: Improves physical function | Randomized trial4 months | 155 people82 ± 6 yearsOlder adults; geriatric patients hospitalized for acute somatic illness | Journal of the American Medical Directors Association, Dec 9, 2016 |
down: Decreases fear of falling-4.02 FES-I points; 95% CI -5.95 to -2.1 down: Decreases anxiety and depression-1 HADS point; 95% CI -1.6 to -0.3 no change: Has no effect on falls | Randomized trial12 months | 415 peopleBoth≥ 60 yearsOlder adults; community-dwelling older adults with excessive fear of falling attending falls services | Health technology assessment (Winchester, England), Jul 1, 2016 |
down: Decreases insomnia up: Improves health-related quality of life no change: Has no effect on physical disability | Randomized trial4 months | 141 people60 years and olderOlder adults; Rural adults with generalized anxiety disorder | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, Apr 15, 2016 |